Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Moderna doses first patient in Phase 3 trial mRNA cytomegalovirus vaccine

By Brian Buntz | October 26, 2021

ModernaModerna CEO Stéphane Bancel has stressed that the company is not just a COVID-19 vaccine maker.

Now, Cambridge, Massachusetts–based Moderna (NSDQ:MRNA) has announced that its mRNA-based cytomegalovirus (CMV) vaccine candidate is entering a Phase 3 pivotal registration study.

“Moderna has been focusing on a vaccine against CMV for a number of years,” said Lori Panther, vice president, clinical development, infectious diseases at Moderna. “We’re very excited to launch this Phase 3 trial.”

While there are currently no licensed CMV vaccines available, researchers have worked on developing such a vaccine for decades. In 1999, the Institute of Medicine assigned a CMV vaccine the highest priority in its assessment of targets for vaccine development. “It’s certainly an unmet medical need,” Panther said. 

Known as mRNA-1647, the investigational vaccine integrates six mRNAs in a single vaccine.

Dr. Lori Panther

Dr. Lori Panther

Five mRNAs encode the subunits that form the membrane-bound pentamer complex. The sixth mRNA encodes the full-length membrane-bound glycoprotein B (gB). “The pentamer antigen actually plays a pretty significant role in terms of viruses’ ability to enter and infect cells,” Panther said. 

CDC notes that more than half of U.S. adults have been infected with CMV by the age of 40. Expectant mothers can pass the virus on to unborn children. One out of 200 newborns has the virus. Roughly one in five babies with the virus has health problems stemming from the infection, including jaundice, low birth weight, hearing loss, seizures and blindness. In addition, CMV in newborns is often linked to congenital disabilities in the U.S.

“Mothers aren’t screened for CMV infection during their pregnancy,” Panther said. “That would require a lot of infrastructure and a lot of cost to periodically screen mothers throughout pregnancy.”  

“We believe that our mRNA vaccine technology is well-suited to provide protection against this latent virus,” Bancel said in a news release.

Moderna is referring to the Phase 3 study as “CMVictory.” It is the second Phase 3 study in its history.

The CMVictory trial will be powered to show vaccine efficacy with biostatistical power in the seronegative population. The study will also include seropositive participants.

The company is also developing vaccine candidates for Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), varicella-zoster virus (VZV), among others.

Moderna said it intends to optimize for diversity in the clinical trial.


Filed Under: Infectious Disease
Tagged With: birth defects, CMV, CMVictory, covid-19, cytomegalovirus, Moderna, mRNA-1647
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE